ESMO20: olaparib recommended for combination with bevacizumab in ovarian cancer

Olaparib, also known as Lynparza, has been recommended for marketing authorization in the EU in combination with bevacizumab for the first-line maintenance treatment of patients with homologous recombination deficient (HRD)-positive advanced ovarian cancer. The recommendation, from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency, was based on the recently published PAOLA-1 Phase III trial (NCT02477644). José Baselga, Executive Vice President at AstraZeneca (MD, USA) – the company responsible for olaparib – commented: “Half of all newly diagnosed patients with advanced ovarian cancer have HRD-positive tumors. Lynparza together with bevacizumab has demonstrated a median PFS...